NCT04458051CompletedPhase 3
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 767
- Locations
- 415
- Primary Endpoint
- 6-month composite Confirmed Disability Progression (cCDP)
Study Overview
Brief Summary
Primary Objective:
To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)
Secondary Objectives:
To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168
Detailed Description
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 12 to 60 months.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 to 55 years of age inclusive
- •Diagnosis of PPMS according to the 2017 McDonald criteria
- •Expanded disability status scale (EDSS) score between 2.0 to 6.5 points, at screening inclusive
- •Positive cerebrospinal fluid oligoclonal bands and/or elevated Immunoglobulin G (IgG) index either during screening or documented previous history.
- •Contraceptive use consistent with local regulations for individuals participating in clinical studies
- •Participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •Is not a woman of childbearing potential (WOCBP) or is a WOCBP and agrees to use an acceptable contraceptive method
- •the participant must not have access to ocrelizumab (eg, ocrelizumab not available on the national market or not reimbursed for the approved indication).
- •the participant must have access to and be eligible to be treated with ocrelizumab but: 1) does not tolerate it due to side effects or safety reasons; and/or 2) has failed ocrelizumab treatment due to perceived lack of efficacy
Exclusion Criteria
- •Participants are excluded from the study if any of the following criteria apply:
- •Participant has conditions that would adversely affect study participation such as short life expectancy.
- •Evidence of infection with human immunodeficiency virus (HIV), transplantation, progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infection that would adversely affect study participation.
- •Persistent chronic or active or recurring system infection that may adversely affect participation or IMP administration in this study as judged by the investigator
- •History of malignancy within 5 years prior to screening.
- •History of alcohol or drug abuse within 1 year prior to Screening.
- •Hospitalized for psychiatric disease within 2 years prior to Screening.
- •Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at Screening.
- •A bleeding disorder or known platelet dysfunction at any time prior to the screening visit.
- •A platelet count <150 000/μL at the screening visit.
- •A history of significant bleeding event within 6 months prior to screening, according to the Investigator's judgment such as, but not limited to cerebral or gastrointestinal
- •Lymphocyte count below the lower limit of normal at Screening.
- •Recent live (attenuated) vaccine within 2 months before the first treatment visit.
- •Recent major surgery (within 4 weeks of Screening) or planned major surgery during the study.
- •The participant has received medications/treatments for MS within a specified time frame.
- •Receiving potent and moderate inducers of cytochrome P450 3A (CYP3A) or potent inhibitors of CYP2C8 hepatic enzymes.
- •Receiving anticoagulant or antiplatelet therapy (such as aspirin >81mg/day, clopidogrel, warfarin).
- •Contraindications to magnetic resonance imaging (MRI).
- •NOTE: Other Inclusion/Exclusion criteria may apply. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Arms & Interventions
Placebo
Placebo Comparator
Placebo to match the SAR442168 once daily
Intervention: Placebo (Drug)
SAR442168
Experimental
Dose 1 of oral SAR442168 once daily
Intervention: Tolebrutinib (Drug)
Outcomes
Primary Outcomes
6-month composite Confirmed Disability Progression (cCDP)
Time Frame: Up to approximately 60 months
Time to onset of 6-month cCDP defined as follows: Increase over at least 6 months of ≥1.0 point from the baseline expanded disability status scale (EDSS) score when the baseline score is ≤5.5, or ≥0.5 points when the baseline EDSS score is \>5.5, or ≥20% from the baseline T25-FW, or ≥20% from the baseline 9-HPT
Secondary Outcomes
- 6-month Confirmed Disability Progression (CDP)(Up to approximately 60 months)
- 3-month composite Confirmed Disability Progression (cCDP)(Up to approximately 60 months)
- Change in T2 hyperintense lesions by MRI(From screening MRI to approximately 60 months)
- Time to onset of confirmed disability improvement (CDI)(Up to approximately 60 months)
- Percent change in Brain volume (BV)(From 6 months up to approximately 60 months)
- Change in cognitive function as assessed by SDMT(From Baseline up to approximately 60 months)
- Change in cognitive function as assessed by CVLT-II(From Baseline up to approximately 60 months)
- Change in Multiple Sclerosis Quality of Life(From Baseline up to approximately 60 months)
- Safety and Tolerability(From screening up to approximately 60 months)
- Population pharmacokinetics(Months 6, 9 and 12)
- Change in plasma neurofilament light chain (NfL)(From Baseline up to approximately 60 months)
- Change in lymphocyte phenotype subsets(From Baseline up to approximately 60 months)
- Changes in serum Immunoglobulin level(From Baseline up to approximately 60 months)
- Change in serum chitinase-3 like protein 1 (Chi3L1)(From Baseline up to approximately 60 months)
Investigators
Study Sites (415)
Loading locations...
Similar Trials
Completed
Phase 3
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)NCT04411641Sanofi1,131
Active, not recruiting
Phase 2
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisMultiple SclerosisNCT04879628Sanofi129
Active, not recruiting
Phase 2
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT05039840Sanofi109
Terminated
Phase 2
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSCPrimary Sclerosing CholangitisNCT04024813Gilead Sciences1
Completed
Phase 2
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)Sjogren's SyndromeSjögren's SyndromeNCT04572841Sanofi84